COCH
Envoy Medical, Inc.
Next earnings Jul 29, 2026 · consensus $-0.08 EPS, $61.2K rev
Last earnings -0.3% on 2026-05-11
$0.67
▼ -0.95%$0.67▼ -52.39%
over 1Y
L $0.39EODHDH $1.70
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.0%
1W+1.0%
1M-3.6%
3M+2.1%
YTD-4.2%
1Y-52.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Revenue grew 7.1% YoY; but unprofitable (net margin -9857.3%).
Revenue (FY2025) $241K · FY2025
Envoy Medical, Inc. shows $241K in FY2025 revenue (+7.1% YoY), a -9857.3% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $237K | $316K | $225K | $241K |
| Gross profit | — | — | — | — | — |
| Operating income | -$5.20M | -$8.71M | -$18.4M | -$19.3M | -$22.3M |
| Net income | -$252K | -$15.9M | -$29.9M | -$20.8M | -$23.8M |
| Diluted EPS | — | -$1.57 | -$2.54 | -$1.49 | -$1.23 |
| Net margin | — | -6718.6% | -9469.0% | -9242.2% | -9857.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$47.5M
EV / EBITDA—
EV / Sales197.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-46.4%
FCF yield-35.9%
Quality & risk
ROIC (est.)—
Free cash flow-$18.4M
Total debt—
Net cash$3.74M
Altman Z-Score-59.06 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)3.5%
Shareholder yield3.5%
Shares Δ YoY+260.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-05-22). Worth a closer look.
- 8-K Officer / director change2026-06-25
- 8-K Delisting notice2026-05-22
- 8-K Officer / director change2026-05-18
- 8-K Earnings results2026-05-11
- 10-Q Quarterly report2026-05-11
- 8-K Officer / director change2026-04-21
- 10-K/A Restated periodic report2026-04-13
- DEF 14A Proxy statement2026-04-02
- 8-K Auditor change2026-03-31
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-192026-06-25open ↗4Period ending 2026-06-192026-06-23open ↗EFFECTFiling2026-06-16open ↗POS AMFiling2026-06-12open ↗S-8Filing2026-06-12open ↗4Period ending 2026-05-292026-06-04open ↗8-KPeriod ending 2026-05-192026-05-22open ↗8-KPeriod ending 2026-05-122026-05-18open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-14open ↗SCHEDULE 13G/AFiling2026-05-11open ↗10-QPeriod ending 2026-03-312026-05-11open ↗
Frequently asked
- Is Envoy Medical, Inc. (COCH) a buy?
- COCH currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 7.1% YoY; but unprofitable (net margin -9857.3%).
- What is Envoy Medical, Inc.'s quality score?
- COCH scores 25.058823529411764/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001840877, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 1:06:57 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.